Cochrane Review: Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer

Zusammenfassung

# Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. ## BACKGROUND Ovarian cancer is the sixth most common cancer in women world-wide. Epithelial ovarian cancer (EOC) is the most common; three-quarters of women present when disease has spread outside the pelvis (stage III or IV). Treatment consists of a combination of  surgery and platinum-based chemotherapy. Although initial responses to chemotherapy are good, most women with advanced disease will relapse. PARP

Kerninformationen

entional chemotherapy. ## OBJECTIVES To determine the benefits and risks of poly (ADP-ribose) polymerase) inhibitors (PARPi) for the treatment of epithelial ovarian cancer (EOC). ## SEARCH METHODS We identified randomised controlled trials (RCTs) by searching the Cochrane Central Register of Con...

herapy, or PARPi together with conventional chemotherapy versus conventional chemotherapy alone. ## DATA COLLECTION AND ANALYSIS We used standard Cochrane methodology. Two review authors independently assessed whether studies met the inclusion criteria. We contacted investigators for additional da...

t six key comparisons.  The majority of participants had BRCA mutations, either in their tumour (sBRCAmut) and/or germline (gBRCAmut), or homologous recombination deficiencies (HRD) in their tumours. Newly diagnosed EOC Overall, four studies evaluated the effect of PARPi in newly-diagnosed, advanced...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen